PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer


Original post, click here

Verified May 2017 by Memorial Sloan Kettering Cancer Center

Sponsor:

Collaborator:

Samus Therapeutics, Inc.

Information provided by (Responsible Party):

Memorial Sloan Kettering Cancer Center

ClinicalTrials.gov Identifier:

NCT03166085

First received: May 23, 2017

Last updated: May 23, 2017

Last verified: May 2017

The purpose of this study is to decide the best dose of the study drug, PU-H71, that can be given in combination with the standard chemotherapy drug, nab-paclitaxel (Abraxane).

Metastatic Breast Cancer Drug: PU-H71
Drug: Nab-paclitaxel
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Intervention Model Description:

This is an open-label, phase Ib study of PU-H71 plus nab-paclitaxel (Abraxane) in patients with HER2-negative metastatic breast cancer (MBC).

Masking: No masking
Primary Purpose: Treatment

Official Title: A Phase 1b Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer

Primary Outcome Measures:

  • Maximum Tolerated Dose (MTD) [ Time Frame: 1 year ]

    The MTD will be the dose level at which 0/6 or 1/6 patients experience excessive toxicity with the next higher dose having at least 2/3 or 2/6 patients experiencing excessive toxicity. This means that if only 3 patients have been treated at a particular dose level and none of them had excessive toxicity, another 3 patients will be treated to verify that no more than 1 out of 6 patients had excessive toxicity.

Estimated Enrollment: 12
Actual Study Start Date: May 23, 2017
Estimated Study Completion Date: May 2018
Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)
Experimental: PU-H71 With Nab-paclitaxel (Abraxane)

PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle and nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1. Both drugs will be administered on the same day, in sequence, with nab-paclitaxel being administered first followed by administration of PU-H71 as close as possible to 6 hours later (+/-1 hour). PU-H71 will be administered intravenously over a 1 hour period; nab-paclitaxel will be administered per standard guidelines as a 30-minute intravenous infusion.

Drug: PU-H71

PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle

Drug: Nab-paclitaxel

nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1

Other Name: Abraxane

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or older
  • Signed informed consent
  • Patients must have histologically confirmed HER2-negative breast cancer (defined as IHC 0 or 1+ and/or fluorescence in situ hybridization [FISH] < 2.0), that is metastatic in stage
  • For estrogen receptor (ER)-positive breast cancer, patients must be considered refractory to endocrine therapy, having received and progressed through at least one prior line of endocrine therapy, or are intolerant of endocrine therapy
  • All patients must have progressed on at least one line of cytotoxic therapy for metastatic disease
  • Patients must have evidence of progressive disease
  • Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
  • Hematologic parameters: white blood cell (WBC) count of ≥ 3000/ul, absolute neutrophil count (ANC) ≥ 1500/ul, platelets ≥ 100,000/ul, hemoglobin ≥ 9.0 g/dl
  • Non-hematologic parameters: bilirubin ≤ 1.5 mg/dl, AST/ALT ≤ 3.0 x upper limit of normal (ULN) (≤ 5.0 x ULN if liver metastases are involved)
  • Serum creatinine < 1.5 xULN or CrCl > 40 mL/min (measured or calculated using the Cockcroft-Gault formula)
  • An Eastern Cooperative Oncology Group performance status of 0-2
  • Life expectancy of 3 months or more as assessed by the investigator
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • Negative β-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after menopause.
  • Women of childbearing potential must agree and commit to the use of a highly effective method of contraception. Men must agree and commit to use a barrier method of contraception while on treatment and for 3 months after last dose of investigational products.

Exclusion Criteria:

  • Symptomatic brain or CNS metastases. Previously treated and stable CNS disease is allowed.
  • Any of the following for the treatment of cancer within 2 weeks of first study treatment: chemotherapy, immunotherapy, experimental therapy, or biologic therapy.
  • Radiation therapy (other than palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of study treatment
  • Any major surgical procedure within 4 weeks of first study treatment
  • Prior treatment with Abraxane
  • Active liver disease, including viral or other hepatitis, or cirrhosis
  • Pregnancy or lactation
  • Other active infections aside from hepatitis
  • Any other significant medical condition not under control, including any acute coronary syndrome within the past 6 months.
  • Patients with a permanent pacemaker
  • Patients with a QTc > 480 ms in the baseline EKG
  • Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable/evaluable disease
  • Peripheral neuropathy of grade ≥ 2 per NCI CTCAE, Version 4.0, at the time of or within 3 weeks prior to the first study therapy
  • Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results in the judgment of the investigator
  • History of an invasive second primary malignancy diagnosed within the previous 3 years, except for appropriately treated stage I endometrial or cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03166085

Contact: Shanu Modi, MD 646-888-4564 modis@mskcc.org
Contact: Komal Jhaveri, MD 646-888-5157

Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Contact: Shanu Modi, MD    646-888-4564      
Contact: Komal Jhaveri, MD    646-888-5157      
Principal Investigator: Shanu Modi, MD         

Memorial Sloan Kettering Cancer Center

Samus Therapeutics, Inc.

Principal Investigator: Shanu Modi, MD Memorial Sloan Kettering Cancer Center

Additional Information:

Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT03166085     History of Changes
Other Study ID Numbers: 17-093
Study First Received: May 23, 2017
Last Updated: May 23, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Memorial Sloan Kettering Cancer Center:

HER2-Negative
PU-H71
Nab-paclitaxel (Abraxane)
17-093

Additional relevant MeSH terms:

Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 24, 2017